Severe cutaneous reaction due to terazosin

Lancet

Volumn 352, Issue 9123, 1998, Pages 202-203

  Hernández Cano, Natalia ^a   Herranz, Pedro ^b   Lázaro, Teresa E ^b   Mayor, Matías ^b   Casado, Mariano ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

TERAZOSIN;

ADULT; ARTICLE; ASTHENIA; CASE REPORT; HEADACHE; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RASH; VERTIGO;

EID: 0032543941     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)77808-9     Document Type: Article

References (4)

1. 1 Lowe FC. Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. Urology 1994; 44: 46-51.
2. 2 Hosmane BS, Maurath CJ, Jordan DC, Laddu A. Effect of age and dose on the incidence of adverse events in the treatment of hypertension in patients receiving terazosin. J Clin Pharmacol 1992; 32: 434-43.
3. 3 Itskovitz HD. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings. Clin Ther 1994; 16: 490-504.
4. 4 Perkash I. Efficacy and safety of terazosin to improve voiding in spinal cord injury patients. J Spinal Cord Med 1995; 18: 236-39.